Uncategorized

Sanofi defends Dupixent patents, but execs insist it has nothing to do with CEO change

Published

3 weeks ago

on

Sanofi’s interim leadership sought on a Thursday earnings call to quell concerns that its sudden defense of Dupixent’s patents had anything to do with the departure of CEO Paul Hudson.

Related Topics:

Leave a Reply

Your email address will not be published. Required fields are marked *

Trending

Exit mobile version